Filterable spreadsheets of vaccine effectiveness studies included in the weekly summary tables. Separate spreadsheets are available for primary series and booster dose studies.
-
Results & Summaries
-
Results & Summaries
This table summarizes the vaccine effectiveness data for COVID-19 studies conducted globally. This table is updated weekly.
-
Results & Summaries
These forest plots summarize available COVID-19 vaccine effectiveness against Omicron variant by vaccine and population of special interest, and for second booster dose and duration of effectiveness. These forest plots are updated weekly.
-
Results & Summaries
This plot summarizes the available laboratory evidence on the ability of COVID-19 vaccines to neutralize SARS-CoV-2 variants of concern.
-
VIEW-Hub Reports
The VIEW-hub report displays data and figures on the introduction, use, and coverage status of typhoid conjugate, human papillomavirus, pneumococcal, rotavirus, Haemophilus influenzae type b, and inactivated polio vaccines both globally and in the
-
Results & Summaries
This checklist, intended for researchers, aims to improve comparability, consistency and reliability across SARS-CoV-2 neutralization studies thereby increasing utility for vaccine decision-making.
-
VIEW-Hub Reports
The VIEW-hub report displays data and figures on the introduction, use, and coverage status of typhoid conjugate, human papillomavirus, pneumococcal, rotavirus, Haemophilus influenzae type b, and inactivated polio vaccines both globally and in the
-
Methods
This document outlines the methods used in the COVID-19 vaccines effectiveness and impact studies review.
-
VERSE Equity Reports
The Vaccine Economics Research for Sustainability and Equity (VERSE) project evaluated the status of vaccine coverage and equity status in the Democratic Republic of the Congo in 2013. Note: This resource is in French.
-
VIEW-Hub Reports
The VIEW-hub report displays data and figures on the introduction, use, and coverage status of typhoid conjugate, human papillomavirus, pneumococcal, rotavirus, Haemophilus influenzae type b, and inactivated polio vaccines both globally and in the